170 related articles for article (PubMed ID: 35753213)
21. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
22. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
23. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
[TBL] [Abstract][Full Text] [Related]
24. Seroconversion following a booster dose of COVID-19 vaccine in liver transplant recipients: a systematic review and meta-analysis.
Gkoufa A; Lekakis V; Papatheodoridis G; Cholongitas E
Pol Arch Intern Med; 2023 Sep; 133(9):. PubMed ID: 36876925
[TBL] [Abstract][Full Text] [Related]
25. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review.
Chenchula S; Karunakaran P; Sharma S; Chavan M
J Med Virol; 2022 Jul; 94(7):2969-2976. PubMed ID: 35246846
[TBL] [Abstract][Full Text] [Related]
26. Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.
Zhou Q; Zeng F; Meng Y; Liu Y; Liu H; Deng G
Sci Rep; 2023 Jun; 13(1):9893. PubMed ID: 37336939
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
28. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
30. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E; S Fischer ; R Demmer-Steingruber ; Nigg S; Güsewell S; Albrich WC; Rothermundt C; Silzle T; Kahlert CR
ESMO Open; 2022 Oct; 7(5):100587. PubMed ID: 36156449
[TBL] [Abstract][Full Text] [Related]
31. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
[TBL] [Abstract][Full Text] [Related]
33. Uptake of COVID-19 Booster Dose among Saudi Arabian Population.
Alshahrani NZ; Alsabaani AA; Ridda I; Rashid H; Alzahrani F; Almutairi TH; Alzahrani BAS; Albeshri ASS
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888690
[No Abstract] [Full Text] [Related]
34. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D; Sieghart D; Simader E; Tobudic S; Radner H; Mandl P; Göschl L; Koblischke M; Hommer N; Wagner A; Mayer M; Schubert L; Hartl L; Kozbial K; Hofer P; Kartnig F; Hummel T; Kerschbaumer A; Deimel T; Puchner A; Gudipati V; Thalhammer R; Munda P; Uyanik-Ünal K; Zuckermann A; Novacek G; Reiberger T; Garner-Spitzer E; Reindl-Schwaighofer R; Kain R; Winkler S; Smolen JS; Stiasny K; Fischer GF; Perkmann T; Haslacher H; Zeitlinger M; Wiedermann U; Aberle JH; Aletaha D; Heinz LX; Bonelli M
Nat Commun; 2022 Sep; 13(1):5362. PubMed ID: 36097029
[TBL] [Abstract][Full Text] [Related]
35. Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients.
Wroński J; Jaszczyk B; Roszkowski L; Felis-Giemza A; Bonek K; Kornatka A; Plebańczyk M; Burakowski T; Lisowska B; Kwiatkowska B; Maśliński W; Wisłowska M; Massalska M; Ciechomska M; Kuca-Warnawin E
Front Immunol; 2022; 13():1033804. PubMed ID: 36389719
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
[TBL] [Abstract][Full Text] [Related]
38. Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
Liatsou E; Ntanasis-Stathopoulos I; Lykos S; Ntanasis-Stathopoulos A; Gavriatopoulou M; Psaltopoulou T; Sergentanis TN; Terpos E
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190194
[TBL] [Abstract][Full Text] [Related]
39. The antibody response of haematological malignancies to COVID-19 infection and vaccination.
Seebacher NA
Br J Cancer; 2022 Mar; 126(5):691-692. PubMed ID: 35017657
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 vaccination in cancer patients: a narrative review.
Seneviratne SL; Yasawardene P; Wijerathne W; Somawardana B
J Int Med Res; 2022 Mar; 50(3):3000605221086155. PubMed ID: 35313761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
